Glenmark announces 400 mg 'FabiFlu' for COVID-19 treatment | WeForNews | Latest News, Blogs Glenmark announces 400 mg ‘FabiFlu’ for COVID-19 treatment – WeForNews | Latest News, Blogs
Connect with us

Disaster

Glenmark announces 400 mg ‘FabiFlu’ for COVID-19 treatment

Published

on

Glenmark Fabiflu

Glenmark Pharmaceuticals, a research-led global pharmaceutical company, on Thursday announced that it is set to introduce a 400 mg version of oral antiviral – FabiFlu — for the treatment of mild to moderate COVID-19 in India.

It was the first Indian company to commercially launch an antiviral drug – Favipiravir with brand name FabiFlu – for the treatment COVID-19 patients. The company received marketing and manufacturing approval from the Drug Controller General of India and launched the product in the Indian market on June 20.

According to the company, the higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day.

Earlier, the 200 mg dosage of FabiFlu required patients to take 18 tablets on Day 1, followed by 8 tablets each day thereafter for a maximum of 14 days.

A higher pill burden has been associated with lower adherence to therapy, the latter affecting viral suppression and overall treatment outcomes. Reducing the pill burden has also been a demand from doctors and patients to enable adherence, the company said.

“With the new 400 mg version, patients will now have a more relaxed dosage regimen, with 9 tablets required on Day 1, and thereafter 2 tablets twice a day from Day 2 till end of the course,” Glenmark Pharmaceuticals added.

Explaining the significance of this development, Monika Tandon, Vice President and Head, Clinical Development of Glenmark Pharmaceuticals Limited said, “The 200 mg dosage of FabiFlu was developed in line with global formulations of the drug Favipiravir, which had similar strength. The 400 mg version is a result of Glenmark’s own R&D efforts to improve treatment experience for patients in India.”

She added, “Being the first company to launch Favipiravir in India, we continue to innovate and seek new treatment options for Covid-19 patients. Introducing this higher strength of FabiFlu is in line with these efforts to ensure a smoother experience for patients, by reducing their daily pill burden.”

Glenmark has also commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in a large pool of patients prescribed with the oral antiviral Favipiravir, as part of an open label, multicentre, single arm study.

It is also conducting another Phase III clinical trial to evaluate the efficacy of two antiviral drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalized adult Covid-19 patients in India.

The combination study which is called the FAITH trial is looking to enrol 158 hospitalized patients of moderate Covid-19 in India. Early treatment with combination therapy will be evaluated for safety and efficacy as it is emerging as an effective approach in shortening duration of virus shedding, facilitating early clinical cure and discharge of patients.

Disaster

Serum Institute CEO has a question for govt: ‘Will it have Rs 80k cr to give each Indian Covid vaccine’

Serum Institute of India has the licence to produce and market two of the leading vaccine candidates, one being developed by AstraZeneca and the Oxford University, and the other one by US company Novavax.

Published

on

Covid 19 Vaccine

New Delhi: Serum Institute of India (SII) CEO Adar Poonawala Saturday asked if the government will have Rs 80,000 crore available over the next one year to buy and distribute the Covid-19 vaccine.

Terming it as “next concerning challenge” that needs to be tackled, Poonawala tweeted, “Quick question; will the government of India have 80,000 crores available, over the next one year? Because that’s what @MoHFW_INDIA needs, to buy and distribute the vaccine to everyone in India.”

He also tagged the prime minister’s office in his tweet. “I ask this question, because we need to plan and guide, vaccine manufacturers both in India and overseas to service the needs of our country in terms of procurement and distribution,” he added.

SII, the world’s largest vaccine manufacturer, has the licence to produce and market two of the leading vaccine candidates, one being developed by AstraZeneca and the Oxford University, and the other one by US company Novavax. The Oxford University vaccine is currently undergoing phase-II and phase-III trials in India. Earlier, the institute had announced that it will make the Oxford vaccine available at USD 3 for low-and-middle-income countries including India.

Apart from bringing some of the leading contenders of a coronavirus vaccine to India, the Serum is developing its own vaccine as well. It is partnering with SpyBiotech, a spin-off of Oxford University, for this purpose. Their vaccine candidate has entered into combined phase-I/phase-II clinical trials, which are being done in Australia. The trials began in the first week of September.

Meanwhile, while addressing the United Nations General Assembly (UNGA), Prime Minister Narendra Modi has said that as the largest vaccine producing country of the world, India’s vaccine production and delivery capacity will be used to help people across the world. “As the largest vaccine producing country of the world, I want to give one more assurance to the global community today. India’s vaccine production and delivery capacity will be used to help all humanity in fighting this crisis,” PM Modi said.

Continue Reading

Cities

Another earthquake jolts Jammu and Kashmir

Published

on

Earthquake Strong

An earthquake measuring 4.5 on the Richter Scale jolted Jammu and Kashmir on Saturday. According to the National Centre for Seismology (NCS), the tremors were felt at 12:02 pm today.

The epicentre of the earthquake was yet not known.

There were no immediate reports of any loss of life or damage to property due to the earthquake.

More to follow…

Continue Reading

Disaster

WHO Board to get 1st update from Covid panel on Oct 5-6, report next year

A diplomat said it is improbable that the independent panel set up by the WHO would be severely critical of the WHO’s handling of the disease in context of China

Published

on

Xi Jinpin and UN Chief

The independent panel on Covid-19 announced by World Health Organisation director general Tedros Adhanom Ghebreyesus in July will submit its first update to the world body’s executive board at its meeting on 5-6 October.

The panel was set up at the World Health Assembly against the backdrop of sharp criticism aimed at the WHO chief and Beijing for their handling of the contagious virus that is believed to have originated in China’s Wuhan. Beijing locked down domestic travel in the early weeks of the infection but allowed flights to freely leave the country, spreading virus across the globe.

At last count, John Hopkins University tracker of Covid-19 infections across the world indicates the virus has infected more than 31 million people worldwide and almost killed a million people. China, from where the disease started late last year, has reported only a small proportion of infections, less than even Oman’s 95,000 cases. The United States and India are among those hit hardest.

The US had led the demand for an independent review of WHO’s response that was seen to have let Beijing guide its hand in the early days of the pandemic. At the UN General Assembly this week, Donald Trump – who pulled out the US from the world health body over its handling of the disease – lashed out at China again and asked the UN to hold China “accountable” for unleashing “this plague” on the world.

Diplomats in New Delhi and Geneva, however, suggest that this is unlikely to happen. One of them said it was improbable that the independent panel – co-chaired by former Prime Minister of New Zealand Helen Clark and former President of Liberia Ellen Johnson Sirleaf – would be critical of the WHO’s handling of the disease in context of China.

Already, Tedros and the independent panel have made it clear that the exercise was not a fault-finding exercise but an effort to improve the world’s response to the next pandemic.

“While we are clear that The Independent Panel must shed light on what has happened and why, this exercise is not a blame game” said Helen Clark, former Prime Minister of New Zealand and Co-Chair of the Panel at its first meeting last week, according to an official statement.

The panel’s co-chair Ellen Johnson Sirleaf said she hoped their report would lead to “bold, credible, robust and implementable solutions that ensure our world is better prepared for the next pandemic”.

The panel is scheduled to submit its final report before the next World Health Assembly (WMA) in May next year but will come up with regular updates for other meetings. Like when the WHO’s top policy-making body, the WMA, resumes its meeting on 9-14 November.

The US isn’t part of the panel. Preeti Sudan, a retired civil servant who was India’s Union health secretary when the coronavirus disease broke out, is a member of the WHO panel.

China has sent Zhong Nanshan, the pulmonologist who is credited by Chinese media for having spearheaded the country’s fight against the outbreak of a new coronavirus that causes Covid-19.

Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.